Elusys Therapeutics

What Elusys Therapeutics does

Elusys Therapeutics is a privately held biopharmaceutical company founded in 1998 and headquartered in Parsippany, New Jersey, with additional operations in Boca Raton, Florida and Research Triangle Park, North Carolina. The company develops monoclonal antibody therapeutics against Category A biothreat agents, with its core product ANTHIM (obiltoxaximab) — an FDA-approved anthrax antitoxin designed to bind and neutralize the protective antigen of Bacillus anthracis — administered in combination with antibacterial therapy for treatment of inhalational anthrax and post-exposure prophylaxis. ANTHIM was approved by the FDA in March 2016 under the Animal Rule, by Health Canada in July 2020 under the Extraordinary Use New Drug pathway, and in 2020 received EU and UK marketing authorization under the trade name Obiltoxaximab SFL; the pipeline also includes LAV-BASTA-48, a single-dose live attenuated vaccine against multi-drug-resistant anthrax developed in partnership with the Israel Institute for Biological Research.

The company's go-to-market is exclusively government procurement: it has been awarded more than $450 million in cumulative contracts by BARDA, NIAID, and the Department of Defense, with total government contracts now exceeding $500 million, and ANTHIM has been procured for the U.S. Strategic National Stockpile and allied government stockpiles worldwide. Revenue is generated through multi-year government procurement contracts (with supplemental R&D development funding) for biodefense medical countermeasure stockpiling, including a CAD $7.9 million first-international contract with the Public Health Agency of Canada in 2022.

Elusys operates with 11–50 employees, maintains 100% domestic sourcing and production, and is led by founder Jeffrey Wolf (Chairman and CEO), supported by a lean executive team whose structure emphasizes regulatory affairs, government affairs and business development, manufacturing/CMC, and quality assurance — all functions aligned to sustaining stockpile procurement and advancing the LAV-BASTA-48 pipeline.

Name

Elusys Therapeutics

Legal name

Elusys Therapeutics, Inc.

Website

https://elusys.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

Elusys Therapeutics is a privately held biopharmaceutical company developing FDA-approved monoclonal antibody medical countermeasures for U.S. federal and allied government biodefense stockpiles, anchored by ANTHIM (obiltoxaximab) for inhalational anthrax.

Ownership category

akta.pro rank

Product category

Biodefense Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Monoclonal antibody therapeutics
• Biodefense medical countermeasures
• Anthrax antitoxin
• Infectious disease treatment
• Government biodefense

Headquarters

HQ city

Pine Brook

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Others

Revenue model

1. U.S. Government Contracts: Elusys has been awarded over $450 million in procurement and development contracts by BARDA, NIAID, and DoD. Revenue is generated through multi-year government procurement contracts for ANTHIM stockpiling.
2. Strategic National Stockpile Procurement: ANTHIM has been procured for the U.S. Strategic National Stockpile and other allied government stockpiles around the world, generating revenue through stockpile procurement contracts.
3. International Government Procurement: International sales to allied governments including Canadian government contract for ANTHIM delivery to NESS (CAD $7.9 million), representing first international sale.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Elusys Therapeutics develops and manufactures monoclonal antibody therapeutics as medical countermeasures against bioterrorism and high-consequence biological threats. Its primary commercial product is ANTHIM (obiltoxaximab), an FDA-approved anthrax antitoxin for the treatment of inhalational anthrax, procured for the U.S. Strategic National Stockpile and allied government stockpiles. The company also maintains a pipeline of additional anthrax and biodefense countermeasures developed with U.S. government partners.

Product overview

Elusys Therapeutics is a biopharmaceutical company developing medical countermeasures against bioterrorism and high-consequence biological threats. The company's portfolio centers on ANTHIM® (obiltoxaximab), an FDA-approved monoclonal antibody anthrax antitoxin, which is procured for national stockpiles including the U.S. Strategic National Stockpile and Canada's National Emergency Strategic Stockpile. The pipeline includes LAV-BASTA-48, a live attenuated anthrax vaccine in preclinical development. The company operates through partnerships with U.S. government agencies including BARDA, NIAID, DoD, and the Strategic National Stockpile.

Differentiator

Problem solved

Functional benefit

Brands

• ANTHIM (obiltoxaximab): FDA-approved monoclonal antibody anthrax antitoxin for treatment of inhalational anthrax. Administered in combination with antibacterial therapy.
• LAV-BASTA-48

Products and services

• ANTHIM® (obiltoxaximab) ANTHIM is an FDA-approved monoclonal antibody anthrax antitoxin designed to bind and neutralize anthrax toxins. It is administered in combination with appropriate antibacterial therapy for the treatment of inhalational anthrax and for post-exposure prophylaxis when alternative therapies are not available. It is procured for the U.S. Strategic National Stockpile and other allied government stockpiles worldwide.
• LAV-BASTA-48 Live attenuated single-dose spore-based MDR-Anthrax vaccine based on disruption of the htrA gene and mutations in the lef and cya genes, designed to provide protection against Multi-Drug Resistant Anthrax with potentially single-dose efficacy. Developed in partnership with the Israel Institute for Biological Research.

Quantifiable outcome

• ANTHIM procurement for U.S. Strategic National Stockpile strengthens biosecurity against potential anthrax attack
• +2 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Public Health Agency of CanadacoreChannel Partner/ Reseller/ Distributor · 27 April 2022Contract with Canadian government to deliver ANTHIM to Canada's National Emergency Strategic Stockpile (NESS). First international sale of ANTHIM valued at CAD $7.9 million.
• Israel Institute for Biological Research (IIBR)coreStrategic or Co-development PartnerElusys partnered with IIBR for LAV-BASTA-48 anthrax vaccine development. The Israel-based institute is collaborating on final IND-enabling efficacy studies and process development for the live attenuated single-dose MDR-anthrax vaccine.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Emergent BioSolutions: Emergent BioSolutions is a direct peer as a leading biodefense contractor with an established anthrax vaccine franchise (BioThrax/ACAM2000) and broader portfolio of FDA-approved medical countermeasures. Like Elusys, Emergent derives substantial revenue from US government stockpiling contracts, and both companies compete for BARDA and DoD procurement dollars.
• SIGA Technologies: SIGA Technologies is a direct peer as a biodefense-focused company with TPOXX (tecovirimat), the FDA-approved antiviral for smallpox treatment. Both companies operate under the same biodefense procurement model with US Strategic National Stockpile contracts and similar BARDA-funded development pipelines targeting Category A pathogens.
• Bavarian Nordic: Bavarian Nordic is a direct peer as a biodefense vaccine developer with JYNNEOS, the FDA-approved smallpox and mpox vaccine, plus pipeline programs targeting other Category A threats. Both companies focus on government stockpiling markets and operate in the same regulatory pathway (FDA Animal Rule and priority review pathways).

Emerging players

• Altimmune: Altimmune is an emerging player in biodefense with NasoShield, a next-generation anthrax vaccine in clinical development. Both companies target anthrax countermeasures for US government stockpiles, though Altimmune is in earlier-stage development without an approved product.
• Soligenix: Soligenix is an emerging player developing medical countermeasures for biodefense threats, including VeloThrax (anthrax vaccine) and treatments for ricin and emerging viral threats. Both companies operate in the BARDA-funded biodefense development ecosystem targeting Category A pathogen preparedness.
• Tonix Pharmaceuticals: Tonix Pharmaceuticals is an emerging player with a biodefense portfolio including next-generation smallpox vaccines and recombinant protective antigen anthrax vaccine. Both companies compete for BARDA and DoD funding in the anthrax countermeasure category.
• Chimerix: Chimerix is an emerging biodefense player developing small molecule antivirals for smallpox and other Category A threats, with a similar BARDA-funded business model. While Elusys focuses on monoclonal antibodies and Chimerix on small molecules, both target government biodefense stockpiling.
• Humanigen: Humanigen is an emerging clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for infectious diseases and inflammatory conditions. Both companies leverage monoclonal antibody platforms targeting infectious disease threats, though Humanigen has focused more on pandemic-related indications.

Others

• DynPort Vaccine Company: DynPort Vaccine Company is a biodefense-focused contract research organization that develops medical countermeasures for DoD and other federal agencies. While not a direct competitor, DynPort operates in the same biodefense development ecosystem and may partner or compete with Elusys on government contracts.
• Resilience (formerly Ology Bioservices): Resilience is a biologics manufacturing and development company that emerged from Ology Bioservices, a biodefense contract manufacturer. As Elusys outsources CMC/manufacturing to CDMOs, Resilience represents both a potential manufacturing partner and a competitor for biodefense manufacturing contracts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/elusys-therapeutics-inc.

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elusys Therapeutics